Expert Interview
A Second Look: Discussing the Future Treatment Landscape for Hidradenitis Suppurativa and the Potential of Izokibep, Povorcitinib and Sonelokimab from Affibody AB, Incyte and Moonlake Immuntotherapeutics
Ticker(s): MLTX, INCY, Affibody ABInstitution: Ruhr-University Bochum and the International Centre for Hidradenitis Suppurativa (ICH)
- Professor of Dermatology; Head of Dermatologic Surgery and Director of the International Centre for Hidradenitis Suppurativa (ICH) at Ruhr-University Bochum
- Treats hundreds of moderate-to-severe hidradenitis suppurativa (HS) patients, including complex surgical referrals from across Europe, within one of the largest specialized HS centers globally
- Internationally recognized KOL in hidradenitis suppurativa (acne inversa) and dermatologic surgery; founded one of Europe’s largest dedicated HS centers and leads an international referral program for severe disease . Actively leads and participates in multinational clinical trials, consensus guidelines, and Delphi panels for HS management, with extensive peer-reviewed publications advancing both medical and surgical treatment strategies. His research focuses on optimizing patient stratification, integrating surgical and biologic therapies, and improving outcomes in refractory inflammatory skin disease.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
